Bulk Pharmaceutical API Sources for ROCEPHIN

Bulk Pharmaceutical API Sources for ROCEPHIN

Vendor	Vendor Homepage	Vendor Sku	API Url
Hangzhou APIChem Technology		AC-1592
Molport		MolPort-005-933-495
AKos Consulting & Solutions		AKOS015960618
Finetech Industry Limited		FT-0623534
AbaChemScene		CS-2948
MedChemexpress MCE		HY-B0712

API Sources for ROCEPHIN (Ceftriaxone Sodium)

Last updated: February 20, 2026

ROCEPHIN (ceftriaxone sodium) is a third-generation cephalosporin antibiotic used globally for bacterial infections. It is manufactured through complex chemical synthesis, requiring high-purity active pharmaceutical ingredient (API) sources. The global supply chain of ceftriaxone sodium relies on multiple bulk API manufacturers, primarily located in India, China, and Europe.

Key API Manufacturers for Ceftriaxone Sodium

Manufacturer	Location	Production Capacity	Certification & Compliance	Key Notes
Mylan (now part of Viatris)	India	Approx. 10,000 tons/year	WHO GMP, US FDA, EMA	Major supplier, historically significant in global supply
Aurobindo Pharma	India	8,000+ tons/year	WHO GMP, US FDA	Supplies APIs for multiple antibiotics including ceftriaxone
Sandoz (Novartis)	Europe	Confidential	EU GMP, US FDA	Supplies from European facilities; smaller share but high compliance standards
Zhejiang Hisun Pharmaceuticals	China	Estimated 5,000+ tons/year	GMP China, US FDA	Growing presence; exports to North America and Europe
Teva Pharmaceuticals	Israel	Confidential	GMP standards	Licenses ceftriaxone API from other suppliers, active in generic formulations

Indian API Suppliers

India's API manufacturing capacity dominates the ceftriaxone sodium supply chain, facilitated by integrated manufacturing facilities compliant with international standards:

• Aurobindo Pharma: Capable of producing multiple formulations and APIs, including ceftriaxone sodium, with a focus on export markets under strict GMP compliance [2].
• Astellas (via licensing): In some cases, manufacturing licenses are held by Astellas and sublicensed globally, influencing availability and pricing.

Chinese API Suppliers

Chinese firms have expanded API production capacity:

• Zhejiang Hisun Pharmaceuticals: Has invested heavily in ceftriaxone sodium manufacturing, exporting primarily to Asia, Africa, and Latin America [3].
• Shanghai Pharmaceuticals: Produces APIs for local distribution and export; their capacity influencing global pricing trends.

European API Suppliers

European manufacturers typically operate at smaller scales with stringent quality standards:

• Sandoz / Novartis: Operate facilities in Europe producing ceftriaxone sodium under EU GMP standards.
• European Contract Manufacturing: Supply to major pharma companies under contract manufacturing models, affecting bulk API sourcing options.

API Sourcing Trends and Considerations

• Regulatory factors influence sourcing decisions. US FDA and EMA compliance are critical for global markets.
• Supply chain disruptions can arise from geopolitics, raw material shortages, or regulatory changes.
• Pricing dynamics: Indian API producers generally offer lower-cost APIs, but quality and regulatory approvals influence choice.
• Manufacturing consolidation: Limited number of high-capacity, GMP-compliant API producers results in concentrated supply.

Quality and Regulatory Compliance

API suppliers must adhere to relevant standards:

• United States: US FDA 21 CFR Part 210/211, Inspections, and approvals are essential for API validation.
• European Union: EMA guidelines and GMP standards govern quality.
• China and India: Increasingly adopting stricter GMP standards; however, quality consistency remains under scrutiny.

Key Challenges and Strategic Implications

• Validation requirements: Manufacturers and distributors must ensure API sources meet stringent regulatory standards.
• Global procurement risks: Heavy dependence on Indian and Chinese suppliers exposes the supply chain to regional disruptions.
• Diversification: Companies are exploring alternative sources, including European API manufacturers, to mitigate risks.

Summary

India's Aurobindo Pharma and similar firms are primary API sources, with significant contributions from Chinese manufacturers like Zhejiang Hisun. European suppliers like Sandoz operate under high compliance standards but at smaller scales. The industry's competitive landscape is shaped by regulatory compliance, geopolitical factors, and capacity constraints.

---

Key Takeaways

• The main active pharmaceutical ingredient producers for ceftriaxone sodium are Indian (Aurobindo) and Chinese (Zhejiang Hisun) firms.
• European-based API suppliers, such as Sandoz, provide high-compliance products but at a smaller scale.
• API sourcing is impacted by regulatory compliance, supply chain disruptions, and pricing pressures.
• Indian manufacturers dominate low-cost API supply, but quality and compliance are critical for global markets.
• Increasing geopolitical and regulatory risks are prompting companies to diversify API sources.

---

FAQs

1. Which countries are the leading producers of ceftriaxone sodium API?
India and China lead in production capacity, with companies like Aurobindo and Zhejiang Hisun providing the majority of API exports.

2. What quality standards do API manufacturers for ceftriaxone sodium need to meet?
Manufacturers must comply with WHO GMP, US FDA 21 CFR standards, and EU GMP, depending on target markets.

3. How has API sourcing impacted global ceftriaxone sodium prices?
Dependence on a limited number of low-cost producers has contributed to price volatility, especially when supply disruptions occur.

4. Are European API suppliers viable alternatives for sourcing ceftriaxone sodium?
Yes; they offer high-quality APIs under strict regulatory compliance but at higher costs and smaller capacities.

5. What are the risks associated with regional API supply chains?
Risks include geopolitical conflicts, regulatory changes, raw material shortages, and logistical bottlenecks, affecting API availability.

---

References

[1] U.S. Food and Drug Administration. (2021). API manufacturing inspections and requirements.
[2] Aurobindo Pharma Limited. (2022). Annual report.
[3] Zhejiang Hisun Pharmaceuticals. (2022). Capacity expansion and export overview.